{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:28:55Z","timestamp":1776482935907,"version":"3.51.2"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.det.2024.08.009","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T19:45:05Z","timestamp":1726602305000},"page":"111-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Innovations in Hyperpigmentation"],"prefix":"10.1016","volume":"43","author":[{"given":"Charissa N.","family":"Obeng-Nyarko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin S.","family":"Puerta Durango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanelle","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jaad.2022.01.051","article-title":"Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders","volume":"88","author":"Wang","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib2","doi-asserted-by":"crossref","first-page":"e2021006","DOI":"10.5826\/dpc.1102a06","article-title":"Confluent and reticulated papillomatosis associated with obesity: case series of three patients successfully treated with oral doxycycline","volume":"11","author":"Lahouel","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1467-2494.2006.00302.x","article-title":"Ethnic skin types: are there differences in skin structure and function?1","volume":"28","author":"Rawlings","year":"2006","journal-title":"Int J Cosmet Sci"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaad.2021.12.065","article-title":"Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation","volume":"88","author":"Ko","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.08.009_bib5","first-page":"20","article-title":"Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color","volume":"3","author":"Davis","year":"2010","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"10.1016\/j.det.2024.08.009_bib6","first-page":"173","article-title":"Emotional benefit of cosmetic camouflage in the treatment of facial skin conditions: personal experience and review","volume":"5","author":"Levy","year":"2012","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.det.2023.02.005","article-title":"Disorders of facial hyperpigmentation","volume":"41","author":"Syder","year":"2023","journal-title":"Dermatol Clin"},{"issue":"10","key":"10.1016\/j.det.2024.08.009_bib8","doi-asserted-by":"crossref","DOI":"10.5070\/D32510045810","article-title":"Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies","volume":"25","author":"Rajanala","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.det.2024.08.009_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/CCID.S158129","article-title":"The impact of acne and facial post-inflammatory hyperpigmentation on quality of life and self-esteem of newly admitted Nigerian undergraduates","volume":"11","author":"Akinboro","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.08.009_bib10","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/molecules25071537","article-title":"Photoprotection and skin pigmentation: melanin-related molecules and some other new agents obtained from natural sources","volume":"25","author":"Solano","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.det.2024.08.009_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/ijdvl.IJDVL_932_17","article-title":"A\u00a0randomized study to evaluate the efficacy and effectiveness of two sunscreen formulations on Indian skin types IV and V with pigmentation irregularities","volume":"85","author":"Sarkar","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"10.1016\/j.det.2024.08.009_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/phpp.12783","article-title":"Melasma: the need for tailored photoprotection to improve clinical outcomes","volume":"38","author":"Morgado-Carrasco","year":"2022","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"3S","key":"10.1016\/j.det.2024.08.009_bib13","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jaad.2021.12.020","article-title":"Misconceptions of photoprotection in skin of color","volume":"86","author":"Taylor","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jaad.2020.04.079","article-title":"Photoprotection beyond ultraviolet radiation: a review of tinted sunscreens","volume":"84","author":"Lyons","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.08.009_bib15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.36849\/JDD.2020.5032","article-title":"Impact of iron-oxide containing formulations against visible light-induced skin pigmentation in skin of color individuals","volume":"19","author":"Dumbuya","year":"2020","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/phpp.12086","article-title":"Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial","volume":"30","author":"Castanedo-Cazares","year":"2014","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"4","key":"10.1016\/j.det.2024.08.009_bib17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2017.01.036","article-title":"Postinflammatory hyperpigmentation: a comprehensive overview: treatment options and prevention","volume":"77","author":"Chaowattanapanit","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib18","first-page":"19","article-title":"Topical treatments for melasma and their mechanism of action","volume":"15","author":"Gonz\u00e1lez-Molina","year":"2022","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib19","first-page":"1260","article-title":"Comparing the efficacy and tolerability of moderate to severe hyperpigmentation and skin unevenness","volume":"23","author":"Callender","year":"2024","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.08.009_bib20","first-page":"4839","article-title":"Skin pigmentation types, causes and treatment-A review","volume":"28","author":"Thawabteh","year":"2023","journal-title":"Mol Basel Switz"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib21","first-page":"67","article-title":"Efficacy and safety of a new triple-combination agent for the treatment of facial melasma","volume":"72","author":"Taylor","year":"2003","journal-title":"Cutis"},{"key":"10.1016\/j.det.2024.08.009_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/CCID.S202285","article-title":"Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin","volume":"12","author":"Ahmad","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib23","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jocd.13145","article-title":"Topical metformin in the treatment of melasma: a preliminary clinical trial","volume":"19","author":"Banavase","year":"2020","journal-title":"J\u00a0Cosmet Dermatol"},{"key":"10.1016\/j.det.2024.08.009_bib24","first-page":"1","article-title":"Comparing the efficacy of topical metformin and placebo in the treatment of melasma: a randomized, double-blind, clinical trial","author":"Mapar","year":"2019","journal-title":"J\u00a0Pharm Res Int"},{"key":"10.1016\/j.det.2024.08.009_bib25","doi-asserted-by":"crossref","first-page":"1281050","DOI":"10.3389\/fphar.2023.1281050","article-title":"Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis","volume":"14","author":"Mongkhon","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.det.2024.08.009_bib26","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/jocd.14953","article-title":"Safety and efficacy of topical metformin 30% cream versus triple combination cream (Kligman\u2019s formula) in treating melasma: a randomized controlled study","volume":"21","author":"AboAlsoud","year":"2022","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib27","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/ajd.13432","article-title":"Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: a randomised, double-blinded trial","volume":"62","author":"Nguyen","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.08.009_bib28","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1111\/jocd.15048","article-title":"Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%\/ascorbic acid 3% combination cream in the treatment of epidermal melasma","volume":"21","author":"Sepaskhah","year":"2022","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.08.009_bib29","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/ijd.15146","article-title":"A\u00a0comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women","volume":"59","author":"Lima","year":"2020","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.009_bib30","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/jdv.17344","article-title":"Efficacy and safety of topical isobutylamidol thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial","volume":"35","author":"Lima","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.det.2024.08.009_bib31","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jid.2019.02.013","article-title":"Effective tyrosinase inhibition by thiamidol results in significant improvement of Mild to moderate melasma","volume":"139","author":"Arrowitz","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ics.12694","article-title":"Effective reduction of post-inflammatory hyperpigmentation with the tyrosinase inhibitor isobutylamido-thiazolyl-resorcinol (Thiamidol)","volume":"43","author":"Roggenkamp","year":"2021","journal-title":"Int J Cosmet Sci"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jaad.2023.07.1045","article-title":"Best practices in the treatment of melasma with a focus on patients with skin of color","volume":"90","author":"Desai","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.08.009_bib34","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00403-023-02549-x","article-title":"A\u00a0randomized, open-label study to compare two different dosing regimens of oral tranexamic acid in treatment of moderate to severe facial melasma","volume":"315","author":"Bhattacharjee","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ijd.16160","article-title":"The uses of tranexamic acid in dermatology: a review","volume":"62","author":"Kim","year":"2023","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib36","first-page":"220","article-title":"Topical tranexamic acid versus hydroquinone for patients presenting with melasma","volume":"29","author":"Erum","year":"2019","journal-title":"J\u00a0Pak Assoc Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.009_bib37","doi-asserted-by":"crossref","first-page":"e14240","DOI":"10.1111\/dth.14240","article-title":"Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: a split-face comparative clinical, histopathological, and antera 3D camera study","volume":"33","author":"El-Husseiny","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib38","first-page":"18","article-title":"A\u00a0comparative study of 20% azelaic acid cream versus 5% tranexamic acid solution for the treatment of postinflammatory hyperpigmentation in patients with acne vulgaris: a single-blinded randomized clinical trial","volume":"28","author":"Sobhan","year":"2023","journal-title":"J\u00a0Res Med Sci"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jocd.13545","article-title":"New topical tranexamic acid derivative for the improvement of hyperpigmentation and inflammation in the sun-damaged skin","volume":"20","author":"da Silva Souza","year":"2021","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.009_bib40","first-page":"333","article-title":"A\u00a0multi-center, randomized, blinded clinical study evaluating the efficacy and safety of a novel topical product for facial dyschromia","volume":"22","author":"Wang","year":"2023","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib41","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.36849\/JDD.7622","article-title":"Extension phase of a multi-center, randomized, blinded clinical study evaluating the efficacy and safety of a novel topical product for facial dyschromia","volume":"23","author":"Wang","year":"2024","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00403-020-02078-x","article-title":"Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study","volume":"313","author":"Chowdhary","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/12034754211045391","article-title":"A\u00a0review of oral therapies for the treatment of skin hyperpigmentation","volume":"26","author":"Shimshak","year":"2022","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib44","first-page":"14","article-title":"Double-blind, placebo-controlled trial to evaluate the effectiveness of Polypodium leucotomos extract in the treatment of melasma in asian skin: a pilot study","volume":"11","author":"Goh","year":"2018","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/idoj.idoj_495_22","article-title":"Efficacy of oral, topical, and intradermal tranexamic acid in patients with melasma \u2014 a meta-analysis","volume":"15","author":"Panchal","year":"2023","journal-title":"Indian Dermatology Online Journal"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib46","first-page":"50","article-title":"Dermatologic applications of Polypodium leucotomos: a literature review","volume":"14","author":"Segars","year":"2021","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib47","first-page":"400","article-title":"The aqueous extract of Polypodium leucotomos (Fernblock\u00ae) regulates opsin 3 and prevents photooxidation of melanin precursors on skin cells exposed to blue light emitted from digital devices","volume":"10","author":"Portillo","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib48","first-page":"148","article-title":"Role of oral Polypodium leucotomos extract in dermatologic diseases: a review of the literature","volume":"13","author":"Choudhry","year":"2014","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib49","first-page":"19","article-title":"Safety and efficacy of oral Polypodium leucotomos extract in healthy adult subjects","volume":"8","author":"Nestor","year":"2015","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib50","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0043-1772197","article-title":"Cosmetic treatments with energy-based devices in skin of color","volume":"39","author":"Chao","year":"2023","journal-title":"Facial Plast Surg"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib51","first-page":"37","article-title":"Cosmetic procedures in patients with skin of color: clinical pearls and pitfalls","volume":"16","author":"Desai","year":"2023","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.08.009_bib52","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s10103-022-03566-4","article-title":"Efficacy and safety of 755-nm picosecond alexandrite laser with topical tranexamic acid versus laser monotherapy for melasma and facial rejuvenation: a multicenter, randomized, double-blinded, split-face study in Chinese patients","volume":"37","author":"Li","year":"2022","journal-title":"Lasers Med Sci"},{"issue":"8","key":"10.1016\/j.det.2024.08.009_bib53","doi-asserted-by":"crossref","first-page":"e13434","DOI":"10.1111\/srt.13434","article-title":"The 675-nm wavelength for treating facial melasma","volume":"29","author":"Coricciati","year":"2023","journal-title":"Skin Res Technol"},{"issue":"12","key":"10.1016\/j.det.2024.08.009_bib54","doi-asserted-by":"crossref","first-page":"e15970","DOI":"10.1111\/dth.15970","article-title":"Comparison of 1064 nm Q-switched Nd:YAG laser and Jessner peeling in melasma treatment","volume":"35","author":"Ertam Sagduyu","year":"2022","journal-title":"Dermatol Ther"},{"issue":"12","key":"10.1016\/j.det.2024.08.009_bib55","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/ijd.15229","article-title":"A\u00a0split face randomized controlled trial comparing 1,064 nm Q-switched Nd-YAG laser and modified Kligman\u2019s formulation in patients with melasma in darker skin","volume":"59","author":"Dev","year":"2020","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib56","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1080\/09546634.2022.2033674","article-title":"A\u00a0prospective, split-face study comparing 1,064-nm picosecond Nd:YAG laser toning with 1,064-nm Q-switched Nd:YAG laser toning in the treatment of melasma","volume":"33","author":"Hong","year":"2022","journal-title":"J\u00a0Dermatol Treat"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/lsm.23173","article-title":"Treatment of post-inflammatory hyperpigmentation in patients with darker skin types using a low energy 1,927 nm non-ablative fractional laser: a retrospective photographic review analysis","volume":"52","author":"Bae","year":"2020","journal-title":"Laser Surg Med"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/14764172.2013.854121","article-title":"A\u00a0patient with cupping-related post-inflammatory hyperpigmentation successfully treated with a 1,927 nm thulium fiber fractional laser","volume":"16","author":"Lee","year":"2014","journal-title":"J\u00a0Cosmet Laser Ther"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib59","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/DSS.0000000000000642","article-title":"Comparative evaluation of efficacy and tolerability of glycolic acid, salicylic mandelic acid, and phytic acid combination peels in melasma","volume":"42","author":"Sarkar","year":"2016","journal-title":"Dermatol Surg"},{"issue":"11","key":"10.1016\/j.det.2024.08.009_bib60","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1111\/jocd.13725","article-title":"Efficacy and tolerability of chemical peeling as a single agent for melasma in dark-skinned patients: a systematic review and meta-analysis of comparative trials","volume":"19","author":"Dorgham","year":"2020","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.08.009_bib61","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/ijd.14948","article-title":"Efficacy and safety of Jessner's solution peel in comparison with salicylic acid 30% peel in the management of patients with acne vulgaris and postacne hyperpigmentation with skin of color: a randomized, double-blinded, split-face, controlled trial","volume":"59","author":"How","year":"2020","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib62","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaad.2023.02.053","article-title":"Treatment recommendations for acne-associated hyperpigmentation: results of the Delphi consensus process and a literature review","volume":"89","author":"Taylor","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib63","first-page":"158","article-title":"Comparative study of 35% glycolic acid, 20% salicylic-10% mandelic acid, and phytic acid combination peels in the treatment of active acne and postacne pigmentation","volume":"12","author":"Sarkar","year":"2019","journal-title":"J\u00a0Cutan Aesthetic Surg"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib64","first-page":"454","article-title":"Effect of a tranexamic acid, kojic acid, and niacinamide containing serum on facial dyschromia: a clinical evaluation","volume":"18","author":"Desai","year":"2019","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/jocd.15965","article-title":"The efficacy and safety of microneedling with topical tranexamic acid for melasma treatment: a systematic review and meta-analysis","volume":"23","author":"Feng","year":"2024","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib66","doi-asserted-by":"crossref","first-page":"e2023195","DOI":"10.5826\/dpc.1303a195","article-title":"Efficacy and safety of topical tranexamic acid alone or in combination with either fractional carbon dioxide laser or microneedling for the treatment of melasma","volume":"13","author":"Kamal Dawaud","year":"2023","journal-title":"Dermatol Pract Concept"},{"issue":"11","key":"10.1016\/j.det.2024.08.009_bib67","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1111\/jocd.16006","article-title":"Efficacy and safety of laser-related therapy for melasma: a systematic review and network meta-analysis","volume":"22","author":"Ma","year":"2023","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00403-023-02794-0","article-title":"The role of 755-nm alexandrite picosecond laser in melasma management","volume":"316","author":"Pulumati","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"10.1016\/j.det.2024.08.009_bib69","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/DSS.0000000000003523","article-title":"Safety and effectiveness of low-density 1927-nm fractional thulium fiber laser for hyperpigmented scar treatment in Fitzpatrick skin types II\u2013V","volume":"48","author":"Wang","year":"2022","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jocd.13817","article-title":"Laser-assisted delivery of tranexamic acid for melasma: pilot study using a novel 1927 nm fractional thulium fiber laser","volume":"20","author":"Wang","year":"2021","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib71","first-page":"263","volume":"71","author":"Kalasho","year":"2020","journal-title":"J\u00a0Cosmet Sci"},{"issue":"4","key":"10.1016\/j.det.2024.08.009_bib72","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/DSS.0000000000001007","article-title":"Treatment of postinflammatory hyperpigmentation with a combination of glycolic acid peels and a topical regimen in dark-skinned patients: a comparative study","volume":"43","author":"Sarkar","year":"2017","journal-title":"Dermatol Surg"},{"issue":"11","key":"10.1016\/j.det.2024.08.009_bib73","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.36849\/JDD.6182","article-title":"Single-center, prospective, double-blind, evaluator-blind, non-randomized, vehicle-controlled trial with a 1927 Nm non-ablative fractionated laser and topical 0.05% tretinoin lotion for facial dyspigmentation and photodamage","volume":"20","author":"Almukhtar","year":"2021","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib74","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2133.2012.11146.x","article-title":"Frontal fibrosing alopecia and lichen planus pigmentosus: is there a link?","volume":"168","author":"Dlova","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.08.009_bib75","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdcr.2023.10.012","article-title":"Recalcitrant lichen planus pigmentosus treated with topical ruxolitinib","volume":"42","author":"Cornman","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"12","key":"10.1016\/j.det.2024.08.009_bib76","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.annder.2020.06.017","article-title":"Oral tranexamic acid in the Treatment of lichen planus pigmentosus: a prospective study of 20 cases","volume":"47","author":"Zenjari","year":"2020","journal-title":"Ann Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.det.2024.08.009_bib77","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jdcr.2020.06.037","article-title":"A\u00a0case of recalcitrant lichen planus pigmentosus treated by oral isotretinoin","volume":"6","author":"Shah","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"9","key":"10.1016\/j.det.2024.08.009_bib78","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/ijd.13293","article-title":"Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study","volume":"55","author":"Muthu","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2024.08.009_bib79","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jdcr.2023.01.029","article-title":"Picosecond neodymium-doped yttrium-aluminum-garnet laser therapy for pigmentation due to lichen planus pigmentosus in a patient with skin of color","volume":"34","author":"Belzer","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"11","key":"10.1016\/j.det.2024.08.009_bib80","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/DSS.0000000000003902","article-title":"Improvement of lichen planus pigmentosus-like drug reaction using a combination of the fractionated 1,550-nm erbium-doped fiber laser and topical cysteamine cream","volume":"49","author":"Murray","year":"2023","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2024.08.009_bib81","first-page":"9467084","article-title":"Confluent and reticulated papillomatosis successfully treated with topical vitamin A derivative","volume":"2023","author":"Alsulami","year":"2023","journal-title":"Case Rep Dermatol Med"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib82","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamadermatol.2020.4083","article-title":"Use of topical sirolimus (rapamycin) for treating confluent and reticulated papillomatosis","volume":"157","author":"Kurtyka","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.009_bib83","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijwd.2018.08.003","article-title":"Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment","volume":"4","author":"Leung","year":"2018","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib84","first-page":"297","article-title":"Successful management of erythema dyschromicum perstans following topical ruxolitinib therapy","volume":"22","author":"Srinivasan","year":"2023","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.009_bib85","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jdcr.2019.12.015","article-title":"Combination therapy with prednisone and isotretinoin in early erythema dyschromicum perstans: a retrospective series","volume":"6","author":"Diaz","year":"2020","journal-title":"JAAD case reports"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib86","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/lsm.22567","article-title":"Improvement of erythema dyschromicum perstans using a combination of the 1,550-nm erbium-doped fractionated laser and topical tacrolimus ointment","volume":"49","author":"Wolfshohl","year":"2017","journal-title":"Laser Surg Med"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib87","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jocd.12797","article-title":"A\u00a0pilot study of oral tranexamic acid and Glycyrrhizin compound in the treatment of recalcitrant Riehl's melanosis","volume":"18","author":"Xu","year":"2019","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.009_bib88","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/phpp.12907","article-title":"A\u00a0novel treatment for Riehl's melanosis targeting both dermal melanin and vessels","volume":"39","author":"Kim","year":"2023","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"8","key":"10.1016\/j.det.2024.08.009_bib89","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/lsm.23214","article-title":"Successful treatment of Riehl's melanosis with mid-fluence Q-switched Nd:YAG 1064-nm laser","volume":"52","author":"Cho","year":"2020","journal-title":"Laser Surg Med"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib90","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/lsm.23341","article-title":"Non-ablative 1927 nm fractional thulium fiber laser: new, promising treatment modality for Riehl's melanosis","volume":"53","author":"Kim","year":"2021","journal-title":"Laser Surg Med"},{"issue":"6","key":"10.1016\/j.det.2024.08.009_bib91","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/jocd.13153","article-title":"Combination therapy with salicylic acid chemical peels, glycyrrhizin compound, and vitamin C for Riehl's melanosis","volume":"19","author":"Wang","year":"2020","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib92","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5021\/ad.2019.31.2.127","article-title":"Analysis of clinical features and treatment outcomes using 1,064-nm Nd-YAG laser with topical hydroquinone in patients with Riehl's melanosis: a retrospective study in 10 patients","volume":"31","author":"Choi","year":"2019","journal-title":"Ann Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.009_bib93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40257-018-0393-2","article-title":"An update on drug-induced pigmentation","volume":"20","author":"Nahhas","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2024.08.009_bib94","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CCID.S394754","article-title":"Successful treatment of minocycline-induced facial hyperpigmentation with a combination of chemical peels and intense pulsed light","volume":"16","author":"Li","year":"2023","journal-title":"Clin Cosmet Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/phpp.12293","article-title":"Successful treatment of minocycline-induced pigmentation with combined use of Q-switched and pulsed dye lasers","volume":"33","author":"Riemenschneider","year":"2017","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"10","key":"10.1016\/j.det.2024.08.009_bib96","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jdcr.2019.07.030","article-title":"Insight into the mechanisms of type III minocycline-induced pigmentation removal: a case of repeated immediate pigment clearing with the Q-switched 755-nm alexandrite laser over a 13-year period","volume":"5","author":"Loh","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.det.2024.08.009_bib97","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5978\/islsm.17-CR-03","article-title":"Type 2 Minocycline-induced hyperpigmentation successfully treated with the novel 755 nm picosecond alexandrite laser - a case report","volume":"26","author":"Sasaki","year":"2017","journal-title":"Laser Ther"},{"key":"10.1016\/j.det.2024.08.009_bib98","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdcr.2023.10.022","article-title":"Treatment of minocycline-induced hyperpigmentation with 730 nm Ti:sapphire picosecond laser","volume":"43","author":"Alajmi","year":"2024","journal-title":"JAAD Case Reports"},{"issue":"5","key":"10.1016\/j.det.2024.08.009_bib99","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/2211738511666230508161611","article-title":"Global trends of cosmeceutical in nanotechnology: a review","volume":"11","author":"Rohilla","year":"2023","journal-title":"Pharm Nanotechnol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:04:22Z","timestamp":1755695062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0733863524000810"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.08.009","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in Hyperpigmentation","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}